1

1 TITLE: Using a polygenic score to account for genomic risk factors in a model to detect 2 individuals with dilated ascending thoracic aortas

Authors: John DePaolo, MD, PhD,¹ Gina Biagetti, MD,² Renae Judy, MS,¹ Grace J. Wang,
MD,² John Kelly, MD,³ Amit Iyengar, MD,³ Nicholas J. Goel, MD,³ Nimesh Desai, MD, PhD,³
Wilson Y. Szeto, MD,³ Joseph E. Bavaria, MD,³ Michael G. Levin, MD,^{4,5*} Scott M. Damrauer,
MD.^{2,4,5,6*}

7 8

9 Affiliations:

- ¹ Department of Surgery, Perelman School of Medicine, University of Pennsylvania,
- 11 Philadelphia, PA 19104, USA.
- ² Division of Vascular Surgery, Department of Surgery, Perelman School of Medicine,
- 13 University of Pennsylvania, Philadelphia, PA 19104, USA.
- ³ Division of Cardiovascular Surgery, Department of Surgery, Perelman School of Medicine,
- 15 University of Pennsylvania, Philadelphia, PA 19104, USA.
- ⁴ Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of
 Pennsylvania, PA 19104, USA.
- ⁵ Corporal Michael Crescenz VA Medical Center, Philadelphia, PA 19104, USA.
- ⁶ Department of Genetics, Perelman School of Medicine, University of Pennsylvania,
- 20 Philadelphia, PA 19104, USA.
- 21 *co-last authors
- 22 23
- 24 Brief Title : Polygenic score inclusion in aortic dilation risk model
- 25 Word count : 3551
- 26 **References** : 25
- 27 **Tables** : 2
- 28 **Figures** : 3
- 29
- 30

31 Address for correspondence:

- 32 Scott Damrauer, MD
- 33 Division of Vascular Surgery
- 34 Hospital of the University of Pennsylvania
- 35 3400 Spruce Street, 14th Floor South Perelman Center
- 36 Philadelphia, PA 19104
- 37 Office: 215-615-1698
- 38 scott.damrauer@pennmedicine.upenn.edu
- 39
- 40

2

41 Abstract

42 Background:

Ascending thoracic aortic dilation is a complex trait that involves modifiable and non-modifiable risk factors and can lead to thoracic aortic aneurysm and dissection. Clinical risk factors have been shown to predict ascending thoracic aortic diameter. Polygenic scores (PGS) are increasingly used to assess clinical risk for multifactorial diseases. The degree to which a PGS can improve aortic diameter prediction is not known. In this study we tested the extent to which the addition of a PGS to clinical prediction algorithms improves the prediction of aortic diameter.

50 **Methods**:

The patient cohort comprised 6,790 Penn Medicine Biobank (PMBB) participants with available echocardiography and clinical data linked to genome-wide genotype data. Linear regression models were used to integrate PGS weights derived from a large genome wide association study of thoracic aortic diameter in the UK biobank and were compared to the performance of

55 the standard and a reweighted variation of the recently published AORTA Score.

56 **Results:**

57 Cohort participants were 56% male, had a median age of 61 years (IQR 52-70) with a mean 58 ascending aortic diameter of 3.4 cm (SD 0.5). Compared to the AORTA Score which explained 59 28.4% (95% CI 28.1% to 29.2%) of the variance in aortic diameter, AORTA Score + PGS 60 explained 28.8%, (95% CI 28.1% to 29.6%), the reweighted AORTA score explained 30.4% 61 (95% CI 29.6% to 31.2%), and the reweighted AORTA Score + PGS explained 31.0% (95% CI 30.2% to 31.8%). The addition of a PGS to either the AORTA Score or the reweighted AORTA 62 Score improved model sensitivity for the identifying individuals with a thoracic aortic diameter \geq 63 4 cm. The respective areas under the receiver operator characteristic curve for the AORTA 64 65 Score + PGS (0.771, 95% CI 0.756 to 0.787) and reweighted AORTA Score + PGS (0.785,

3

66 95% CI 0.770 to 0.800) were greater than the standard AORTA Score (0.767, 95% CI 0.751 to

- 67 0.783) and reweighted AORTA Score (0.780 95% CI 0.765 to 0.795).
- 68 **Conclusions:**
- 69 We demonstrated that inclusion of a PGS to the AORTA Score results in a small but clinically
- 70 meaningful performance enhancement. Further investigation is necessary to determine if
- 71 combining genetic and clinical risk prediction improves outcomes for thoracic aortic disease.
- 72

4

73 Introduction

74 Thoracic aortic dilation can lead thoracic aortic aneurysm (TAA) development, a life-75 threatening condition. Unimpeded, TAA can progress to acute rupture or acute thoracic aortic dissection, which represent approximately 8% of all out-of-hospital cardiopulmonary arrests.¹ 76 For patients admitted to a hospital for emergent treatment of thoracic aortic aneurysm and 77 dissection (TAAD), observed 30-day mortality is 39-49%.²⁻⁵ Despite the high mortality risk, 78 79 most cases of ascending thoracic aortic dilation and subsequent aneurysm development are asymptomatic and identified incidentally.⁶ When recognized, asymptomatic ascending thoracic 80 81 aortic aneurysms can be monitored with serial imaging and treated with aggressive blood 82 pressure control and elective surgery, yielding significantly improved results when compared to 83 emergency intervention.⁷

Across a range of cardiovascular diseases, polygenic scores (PGS) have become increasingly attractive as predictive tools to utilize in clinical settings to estimate individual level genetic risk for specific diagnoses.⁸⁻¹⁰ We and others have formulated PGSs to assess risk of increased ascending thoracic aortic diameter,^{11,12} and TAAD.¹³ GWAS have identified several genomic loci associated with both ascending thoracic aortic diameter and TAAD, and both traits are heritable, making PGS potentially useful for identifying individuals with enlarged aortas; however, the clinical utility of PGS remain poorly understood.

Recently, a clinical risk score to identify patients at elevated risk for ascending aortic dilation, referred to as the AORTA (aorta optimized regression for thoracic aneurysm) Score, was developed using cardiac magnetic resonance imaging (cMRI) measurements of ascending thoracic aortic diameter among individuals within the UK Biobank (UKB), and validated among subsets of individuals within the Framingham Heart Study (using computed tomography [CT] scans) and Mass General Brigham Biobank (using transthoracic echocardiography [TTE]).¹⁴ The present study validates the AORTA score within a separate

- 5
- 98 diverse population, demonstrates the importance of creating individual population weighted
- 99 values for specific factors in a predictive model, and shows the incremental benefit of including
- 100 a PGS as a component of a combined clinical risk tool.
- 101

102 <u>Methods</u>

103 Study Population

104 Penn Medicine Biobank (PMBB) is composed of individuals recruited from across the

105 Penn Medicine healthcare system. Each participant consents to linkage of electronic health

106 records to biospecimens. A total of 44,297 volunteers have undergone genotyping per

107 standard methodology as previously described.^{15,16} Among these individuals, 6,790 have at

108 least one transthoracic echocardiography (TTE) study with a recorded measurement of

- 109 ascending thoracic aortic diameter.
- 110 Clinical Covariate Selection

We utilized the set of clinical factors identified in the original AORTA Score,¹⁴ including the presence of a diagnosis of hypertension, diabetes, and/or hyperlipidemia, sex, age, body mass index (BMI), weight, height, systolic and diastolic blood pressure, and pulse rate. We also included the previously reported series of interaction terms between the 11 clinical covariates.

116 Prediction model creation

Using the clinical covariates and source code for the AORTA Score model (https://github.com/carbocation/genomisc), we derived predicted ascending thoracic aortic diameter values for PMBB participants and a linear regression model was fit using measured ascending thoracic aortic diameter as the dependent variable. The "AORTA Score + PGS" model was similarly constructed with PGS values included as a covariate for each individual in the PMBB. PGS scores were derived using weights from a previously published weighted

6

123 allele PGS of ascending thoracic aortic diameter among UKB participants genetically similar to the European reference population.¹² This PGS for ascending aortic diameter was constructed 124 125 using 89 autosomal independently significant SNPs from individuals genetically similar to the 126 European reference population in the UKB. Principal components of ancestry were derived for 127 all PMBB participants and included as covariates in the AORTA Score + PGS model. 128 Three additional comparator models were created to assess the performance of the 129 both the AORTA Score and the AORTA Score + PGS among PMBB individuals. First, to 130 improve model performance by leveraging local population health characteristics, a reweighted 131 version of the AORTA Score with clinical weights derived from individuals within PMBB, 132 subsequently referred to as the "reweighted AORTA Score," was created without consideration 133 of PGS or principal components of ancestry. Second, this model was expanded to include the 134 PGS plus the first five PCs of ancestry, which is subsequently referred to as the "reweighted 135 AORTA Score + PGS." Third, an age plus sex model that included both PGS and the first five 136 principal components of ancestry, subsequently referred to as the "Age + Sex + PGS model," 137 was also analyzed to determine the effect of genetic factors without considering clinical risk 138 factors.

139 Model evaluation

To limit over-fitting, performance measures are reported using 5 repeats of 10-fold cross-validation. This repeated cross-validation splits the data evenly 10 times, holds out one of 10 folds for model assessment while the data across the remaining nine folds are used to fit the model. This entire process is repeated five times, resulting in 50 separate model fits/tests. Final resampling estimates of performance average each cross-validated replicate with 95% credible intervals.

Model performance and calibration were evaluated by several methods including *R*squared (RSQ) and root-mean-square error (RMSE) using *yardstick* (v1.2.0),¹⁷ linear

7

148 re	egression effect e	stimate (coefficient	of the slope of the li	inear model), and intercept
--------	--------------------	----------------------	------------------------	-----------------------------

- 149 (calibration). Predicted and residual aortic diameters were plotted against actual
- 150 measurements. Bland-Altman plots were created for each individual model.¹⁸
- 151 Between-model comparisons were systematically made using Bayesian analysis of
- 152 variance (ANOVA) function in the *tidyposterior* package in R (v1.0.0) that relied upon random
- 153 intercept modeling to fully account for resampling by assuming that individual resamples only
- 154 effect the model by changing the intercept.¹⁹ We generated posterior distributions of RSQ and
- 155 RMSE values with corresponding credible intervals to compare individual model performance.
- 156 This allowed the derivation of probability that the proportion of the comparative model RSQ
- and RMSE posteriors are greater than zero; that is, the probability that the estimated
- 158 performance of the two models is different. Posterior distributions were also used to compute
- the probability of being practically equivalent or significant with a practical effect size of +/- 2%,
- 160 also known as the Region of Practical Equivalence (ROPE) estimate.²⁰
- 161 Score Thresholding and Confusion Matrix Analysis

A range of score threshold values between three and four were tested in confusion matrices to assess the appropriate linear model cutoff to optimize sensitivity and specificity and predict ascending thoracic aortic diameter \geq 4 cm. For each respective linear model, score threshold values were set at intervals increasing by five percent, representing the fifth percent highest score to the 50th percent highest score. These thresholds were used to identify the true-positives, false-positives, true-negatives, and false-negatives at any given cutoff value compared to the actual values, and score sensitivity and specificity were analyzed.

169 Binary model construction and Decision Curve Analysis

170Logistic regression models were used to predict the ascending thoracic aortic diameter171 \geq 4 cm based on AORTA Score covariates and PGS. To test prediction performance, the area172under the receiver operator characteristic curve (AUROC) was calculated for each model using

8

173 the *pROC* package in R (v1.18.1).²¹ Ninety-five percent confidence intervals for the AUROC

174 were calculated using the *ci.auc* function.

175 Clinical net benefit was assessed for each logistic regression model using decision 176 curve analysis, an analytic instrument to test the benefit of a diagnostic tool in the presence of 177 competing harms and benefits.^{22,23} Decision curve analysis was performed on each model with 178 "net benefit" defined as cases of ascending thoracic aortic diameter \geq 4 cm identified for 179 screening imaging per 100 individuals. These analyses generate a plot of net benefit as a 180 function of "threshold probability" at which a clinician or individual considers the potential 181 benefit versus harm of undergoing TTE imaging. For instance, if a clinician were to say that there is no harm to unnecessary screening, the "threshold probability" would equal 0%. If, 182 183 however, a clinician believed screening represented an unnecessary risk no matter what could 184 be found on subsequent imaging, the "threshold probability" would equal 100%. TTE imaging 185 has minimal risks, as it is non-invasive, in-expensive, and has no radiation exposure; therefore, 186 the threshold probability assessed in this study was 0-25%. Decision curve analysis was performed using *dcurves* (v0.4.0).²⁴ 187 188 Statistical Analyses 189 Statistical analysis was performed in R version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria). The *Tidymodels* R package (v1.0.0) was used for all model 190

191 cross-validation analysis.²⁵ Throughout this investigation, Bayesian statistics were used to

192 derive posterior probabilities and credible intervals of individual model performance statistics.

193

194 <u>Results</u>

195 Clinical Characteristics

A total of 6790 PMBB participants were included. Forty-four percent of the individuals were female, and the median age was 61 years (IQR 52 – 70) [**Table 1**]. The mean ascending

9

aortic diameter was 3.4 cm, and there were 830 individuals (12%) with an ascending aortic diameter \ge 4 cm. Seventy-four percent of individuals had a history of hypertension, 63% had a history of hyperlipidemia, and 33% had a history of diabetes. Compared to the UKB training cohort from which the AORTA Score was derived, the PMBB cohort had increased prevalence of co-morbidities and larger average ascending thoracic aortic diameter (**Table 1**).

203

204 PMBB Model Calibration and Performance

205 The performance of the standard AORTA Score and each model variation were utilized 206 to estimate the aortic diameter for each PMBB participant within the cohort. For a 1 cm 207 estimate for ascending thoracic aortic diameter using the AORTA Score, the measured aortic 208 diameter was 1.08 cm (95% confidence interval [CI] 1.07 cm to 1.15 cm, P<0.001) suggesting 209 a significant underestimation of aortic diameter; this was not seen with any of the other models 210 (Table S1). Predicted values for individual models were plotted against measured and residual 211 values (Figure S1). In Bland-Altman plots, the 95% limits of agreement of the AORTA Score 212 0.63 cm to -1.04 cm, suggesting the model underestimated large diameters more than it 213 overestimated small diameters, and generally conservative errors (Figure S2). Bland-Altman 214 plots for each of the other comparator models demonstrated more balanced 95% limits of 215 agreement with consistently conservative errors.

Individual model RSQ and RMSE demonstrated that the reweighted AORTA
Score + PGS was the best performing model, and that the addition of PGS a conferred a small
performance improvement on both the AORTA Score and the reweighted AORTA Score
(Table 2). Compared to the AORTA Score which explained 28.4% (95% CI 28.1% to 29.2%) of
the variance in aortic diameter, AORTA Score + PGS explained 28.8%, (95% CI 28.1% to
29.6%), the reweighted AORTA score explained 30.4% (95% CI 29.6% to 31.2%), and the
reweighted AORTA Score + PGS explained 31.0% (95% CI 30.2% to 31.8%).

10

223 To determine specific inter-model performance differences, we applied Bayesian 224 principles to resampled data from PMBB to generate a set of posterior probabilities and 225 credible intervals (CI) for the RSQ and RMSE of each model for ANOVA analysis between models.²⁵ The differences in RSQ between each of AORTA Score versus AORTA Sore + PGS 226 227 (RSQ mean difference 0.002, 95% CI -0.002 to 0.005) and reweighted AORTA Score versus 228 reweighted AORTA Score + PGS (RSQ means difference 0.002, 95% CI -0.001 to 0.006) 229 suggested that the addition of the PGS to either model incrementally improve explanation of 230 variance (Table S2, Figure 1). Comparable results were observed when investigating direct 231 comparison of RMSE between these models suggesting PGS also improves model accuracy 232 (Table S3, Figure S3). However, neither marginal improvement was practically different using 233 a region of practical equivalence (ROPE) of 2% (Tables S4 and S5). These results suggest 234 that the addition of the PGS modestly improves model explanation of variance (RSQ) and 235 accuracy (RMSE) independent of reweighting in a statistically significant but not clinically 236 meaningful manner.

237 As the AORTA Score variables are commonly assessed clinically and require no 238 additional testing, if performance improvements can be made by simple reweighting, a PGS 239 may not be necessary as it may require additional cost/testing. To assess if the addition of a 240 PGS to the standard AORTA Score conferred a similar performance improvement compared 241 as model reweighting, we directly compared AORTA Score + PGS and the reweighted AORTA 242 Score. The reweighted AORTA Score had superior explanation of variance (RSQ mean 243 difference 0.016, 95% CI 0.009 to 0.022) and accuracy (RMSE mean difference 0.005, 95% CI 244 0.002 to 0.008) [Tables S2 and S3, Figures 1 and S3]. However, neither difference achieved likely practical significance (Table S4 and S5). These findings suggest that model reweighting 245 246 based on local baseline health characteristics improves AORTA Score performance marginally 247 more than the addition of a PGS.

11

248

249 Assessing Model Clinical Utility

250 To assess the clinical performance of each model in predicting individuals with aortic 251 diameters ≥ 4 cm, a clinically meaningful threshold at which serial imaging would be 252 recommended, we performed logistic regression analysis using the covariates from the 253 AORTA score, and PGS where indicated, and analyzed receiver operator characteristic curves (ROC) and area under the ROC (AUROC) (Figure 2). The AORTA Score + PGS (AUROC = 254 255 0.771, 95% CI 0.756 to 0.787), reweighted AORTA Score (AUROC = 0.780 95% CI 0.765 to 256 0.795), and reweighted AORTA Score + PGS (AUROC = 0.785, 95% CI 0.770 to 0.800) each 257 better predicted ascending thoracic aortic diameter ≥ 4 cm compared to the standard AORTA 258 Score (AUROC = 0.767, 95% CI 0.751 to 0.783) and Age + Sex + PGS (AUROC = 0.737, 95% 259 CI 0.720 to 0.753). Taken together, these results suggest that the addition of the PGS to the 260 standard and reweighted AORTA Scores improves the ability of either model to predict aortic 261 diameter greater than 4 cm, and that the optimal model is the reweighted AORTA Score + 262 PGS.

263 To investigate whether PGS integration provides net clinical benefit to the AORTA 264 Score, we performed decision curve analyses (DCA) using each logistic regression model. 265 DCA allows the assessment of net clinical benefit which equates to the number of true 266 positives screened less the number of false positives screened at a specific threshold 267 probability.²² In this evaluation, the screening test is a transthoracic echocardiogram, a non-268 invasive and relatively inexpensive procedure. Using a risk threshold of 0-25%, each of the five 269 models evaluated performs better than the "Screen All" or "Screen None" strategies (Table S6, 270 Figure 3). At the threshold probability of 25% for example, the net benefit of the reweighted 271 AORTA Score + PGS logistic regression model was 1.5 cases per 100 individuals screened. 272 This net benefit was increased compared to the reweighted AORTA Score logistic regression

12

273 (net benefit of 1.4 cases per 100 individuals screened), AORTA Score + PGS logistic 274 regression (1.4 cases per 100 individuals screened), the standard AORTA Score logistic 275 regression (1.0 cases per 100 individuals screened), and the Age + Sex + PGS logistic 276 regression (0.2 cases per 100 individuals screened). These data suggest that the addition of 277 the PGS and reweighting the AORTA Score based on local clinical risk factors may slightly 278 enhance the overall clinical utility of the baseline AORTA Score model (approximately 1 279 additional case per 200 individuals screened), and provides further evidence that the addition 280 of a PGS incrementally improves model performance.

281 As a sensitivity analysis we constructed confusion matrices using each linear regression 282 model at different score thresholds and compared model sensitivity and specificity to compare 283 optimal model thresholds that could result in maximized clinical utility to discern individuals 284 who would benefit from screening (Tables S7 and S8). Thresholds were set every five percent from the fifth percentile score to the 50th percentile score. These scores were then 285 286 utilized as cutoff values for predicting a case (ascending thoracic aortic diameter \geq 4 cm) versus controls. Across thresholds, the reweighted AORTA Score + PGS was consistently the 287 288 best performing model; for instance, using the 10th percentile score in every model, the 289 reweighted AORTA Score + PGS had a sensitivity of 29.8% compared to 27.7% for the 290 reweighted AORTA Score, 27.0% for the AORTA Score + PGS, 26.5% for the AORTA Score, 291 and 22.4% for the Age + Sex + PGS. The addition of the PGS frequently contributed to 292 improved model sensitivity supporting our observation that the addition of a PGS incrementally 293 improves model performance.

294

295 **Discussion**

Using a published predictive model of enlarged ascending aortic diameter, we
 demonstrated that the addition of a PGS based on the largest available GWAS of ascending

13

298 thoracic aortic diameter modestly improved standard AORTA Score and reweighted AORTA 299 Score performance by several measures including the explanation of variance (RSQ) and 300 accuracy (RMSE), however these improvements in performance fell within a range of practical 301 equivalence of 2%. The addition of PGS also marginally improved the predictive capacity to 302 identify a rtic diameter \geq 4 cm as determined by AUROC, sensitivity, and overall net benefit in 303 decision curve analyses. Notably, in the sensitivity assessment the addition of the PGS 304 incrementally improved model performance at a range of thresholds suggesting that the benefit 305 is not limited to a narrow cohort with elevated risk. We also demonstrated that using PMBB 306 participant clinical data to reweight the AORTA Score improved model performance more than 307 the addition of the PGS alone, and that the combination of reweighting and PGS created the 308 best performing model.

309 Currently, there are no meaningful recommendations for screening individuals for 310 dilated ascending thoracic aortas who lack a history of familial disease. Our findings are instructive when considering how to clinically implement a screening model for ascending 311 312 thoracic aortic aneurysm. Both the addition of genetic information and reweighting the 313 covariates improved AORTA Score model fit and corrected aortic diameter underestimation 314 observed with the standard AORTA Score model in PMBB. Though the predictive 315 improvement in AORTA Score from the addition of the PGS and/or from reweighting was 316 marginal, both confusion matrix and decision curve analysis suggest that these changes will 317 consistently benefit clinical decision-making more than the current strategy (i.e., screen none) 318 by identifying individuals at risk for a rtic dilation who would benefit from a non-invasive TTE. 319 Furthermore, the addition of the PGS, covariate reweighting, and the combination of both 320 consistently perform better than the standard AORTA Score within the threshold probability 321 ranges assessed.

14

322 AORTA Score covariate reweighting based on local health characteristics easily 323 aggregable from electronic health record (EHR) platforms may offer a more expedient strategy 324 for rapid, optimal clinical implementation of AORTA Score as it avoids reliance on genetic data 325 that are not ubiquitously available. However, in clinical settings where large biobanks have 326 been established, integration of the PGS and reweighting the AORTA Score would most 327 successfully identify individuals who warrant screening TTEs. These centers of care may even 328 consider implementing a program similar to Recall by Genotype (RbG) initiatives where all 329 enrolled individuals are screened using the AORTA Score + PGS and those at elevated risk 330 are contacted and offered TTEs. As genetic data becomes increasingly available due to the 331 rapid speed and availability of whole genome sequencing, integration of a model accounting for both local health characteristics and genetic data may become more universally applicable 332 333 with the potential to more accurately identify individuals who warrant screening. 334 Notably, the modest improvements currently attributable to the PGS are derived from 335 the largest GWAS available for ascending thoracic aortic diameter. This GWAS included 336 38,694 individuals, 2-3% of whom had a ortic diameters \geq 4 cm. Compared to other more 337 powerful PGS available in other cardiovascular diseases, this is a relatively small cohort of 338 individuals from which to derive PGS weights. While ascending thoracic aortic diameter was found to be highly heritable in this GWAS (63%, 95% CI 60–67),¹² even our best-performing 339 340 model explained only a modest proportion of variance in a ortic diameter, and substantially less

341 variability than the anticipated heritability. As GWAS sizes expand and understanding of the

342 genetic underpinnings of ascending aortic diameter and aneurysmal degeneration improve, the AORTA Score enhancement attributable to PGS inclusion will likely continue to grow.

344

343

345 Limitations

15

This study has several limitations. First, both the AORTA Score and the PGS for 346 347 ascending thoracic aortic dilation were derived from the UK Biobank whose participants are 348 largely healthier and less diverse than most of the major urban centers within the US from 349 which regional biobanks like the PMBB are constructed. For instance, not only do PMBB 350 participants have a larger ascending thoracic aortic diameter to begin with (mean 3.36 cm 351 compared to 3.18 cm), but the PMBB training cohort had a higher median BMI (29.3 compared 352 to 25.7), rates of hypertension (73.9% compared to 30.0%), hyperlipidemia (62.9% compared 353 to 21.3%), and diabetes (32.5% compared to 2.9%). While these factors were considered in 354 the reweighted AORTA Score, it remains unclear how these health factors would impact 355 broader implementation of the AORTA Score, and how the underlying genetic risks for these 356 conditions may impact a rtic dilation.

Additionally, this study was limited to a single biobank. The effect of the PGS may be limited as a function of sample size and power. Sensitivity and specificity calculations also depend highly on disease prevalence, which is relatively elevated compared to UKB. Further investigation among other cohorts will contribute to assessing the benefit of including the PGS as a covariate within the AORTA Score.

362 Conclusions

363 Our findings suggest that the reweighted AORTA score model using PMBB data and 364 incorporating PGS weights is the best performing linear regression model to predict enlarged 365 ascending thoracic aortic diameter. Independent of reweighting, the addition of genomic 366 covariates modestly improved overall performance of the standard AORTA Score and the reweighted AORTA Score suggesting that utilization of genetic data may enhance clinical 367 368 outcomes when determining individuals who warrant screening for ascending thoracic aortic 369 dilation. Further research is needed to determine if similar cohorts have improved model 370 performance with the addition of a PGS as a covariate, and whether that improvement

16

- translates to better clinical outcomes among a diverse population with differing levels of
- baseline health.
- 373

374 Acknowledgements

- 375 We thank the participants of the Penn Medicine Biobank. The PMBB is supported by Perelman
- 376 School of Medicine at University of Pennsylvania, a gift from the Smilow family, and the
- 377 National Center for Advancing Translational Sciences of the National Institutes of Health under
- 378 CTSA award number UL1TR001878. J.D. is supported by the American Heart Association
- 379 (23POST1011251). M.G.L. is supported by the Institute for Translational Medicine and
- 380 Therapeutics of the Perelman School of Medicine at the University of Pennsylvania, the
- 381 NIH/NHLBI National Research Service Award postdoctoral fellowship (T32HL007843), the
- 382 Measey Foundation, and the Doris Duke Foundation. S.M.D. is supported by funding from the
- 383 Department of Veterans Affairs Office of Research (IK2-CX001780).

17

385 **References**

- 1. Takeuchi S, Yamaguchi Y, Soejima K, Yoshino H. Incidence and characteristics of
- 387 acute aortic dissection in patients with out-of-hospital cardiopulmonary arrest evaluated
- 388 by non-contrast computed tomography. *Eur Heart J Acute Cardiovasc Care*.
- 389 2020;9:S48-S57. doi: 10.1177/2048872620923647
- 390 2. Howard DP, Banerjee A, Fairhead JF, Perkins J, Silver LE, Rothwell PM, Oxford
- 391 Vascular S. Population-based study of incidence and outcome of acute aortic dissection
- and premorbid risk factor control: 10-year results from the Oxford Vascular Study.
- 393 *Circulation*. 2013;127:2031-2037. doi: 10.1161/CIRCULATIONAHA.112.000483
- 394 3. Landenhed M, Engstrom G, Gottsater A, Caulfield MP, Hedblad B, Newton-Cheh C,
- 395 Melander O, Smith JG. Risk profiles for aortic dissection and ruptured or surgically
- treated aneurysms: a prospective cohort study. *J Am Heart Assoc*. 2015;4:e001513.
- 397 doi: 10.1161/JAHA.114.001513
- 398 4. Melvinsdottir IH, Lund SH, Agnarsson BA, Sigvaldason K, Gudbjartsson T, Geirsson A.
- 399 The incidence and mortality of acute thoracic aortic dissection: results from a whole
- 400 nation study. *Eur J Cardiothorac Surg*. 2016;50:1111-1117. doi: 10.1093/ejcts/ezw235
- 401 5. Trimarchi S, Nienaber CA, Rampoldi V, Myrmel T, Suzuki T, Mehta RH, Bossone E,
- 402 Cooper JV, Smith DE, Menicanti L, et al. Contemporary results of surgery in acute type
- 403 A aortic dissection: The International Registry of Acute Aortic Dissection experience. *J*
- 404 *Thorac Cardiovasc Surg.* 2005;129:112-122. doi: 10.1016/j.jtcvs.2004.09.005
- 405 6. Vilacosta I, San Roman JA, di Bartolomeo R, Eagle K, Estrera AL, Ferrera C, Kaji S,
- 406 Nienaber CA, Riambau V, Schafers HJ, et al. Acute Aortic Syndrome Revisited: JACC
- 407 State-of-the-Art Review. *J Am Coll Cardiol*. 2021;78:2106-2125. doi:
- 408 10.1016/j.jacc.2021.09.022

- 409 7. Wallen T, Habertheuer A, Bavaria JE, Hughes GC, Badhwar V, Jacobs JP, Yerokun B,
- 410 Thibault D, Milewski K, Desai N, et al. Elective Aortic Root Replacement in North
- 411 America: Analysis of STS Adult Cardiac Surgery Database. *Ann Thorac Surg*.
- 412 2019;107:1307-1312. doi: 10.1016/j.athoracsur.2018.12.039
- 413 8. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander
- 414 ES, Lubitz SA, Ellinor PT, Kathiresan S. Genome-wide polygenic scores for common
- 415 diseases identify individuals with risk equivalent to monogenic mutations. *Nat Genet*.
- 416 2018;50:1219-1224. doi: 10.1038/s41588-018-0183-z
- 417 9. O'Sullivan JW, Raghavan S, Marquez-Luna C, Luzum JA, Damrauer SM, Ashley EA,
- 418 O'Donnell CJ, Willer CJ, Natarajan P, American Heart Association Council on G, et al.
- 419 Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the
- 420 American Heart Association. *Circulation*. 2022;146:e93-e118. doi:
- 421 10.1161/CIR.000000000001077
- 10. Sud A, Horton RH, Hingorani AD, Tzoulaki I, Turnbull C, Houlston RS, Lucassen A.
- 423 Realistic expectations are key to realising the benefits of polygenic scores. *BMJ*.
- 424 2023;380:e073149. doi: 10.1136/bmj-2022-073149
- 11. Tcheandjieu C, Xiao K, Tejeda H, Lynch JA, Ruotsalainen S, Bellomo T, Palnati M,
- 426 Judy R, Klarin D, Kember RL, et al. High heritability of ascending aortic diameter and
- 427 trans-ancestry prediction of thoracic aortic disease. *Nat Genet.* 2022;54:772-782. doi:
- 428 10.1038/s41588-022-01070-7
- 429 12. Pirruccello JP, Chaffin MD, Chou EL, Fleming SJ, Lin H, Nekoui M, Khurshid S,
- 430 Friedman SF, Bick AG, Arduini A, et al. Deep learning enables genetic analysis of the
- 431 human thoracic aorta. *Nat Genet*. 2022;54:40-51. doi: 10.1038/s41588-021-00962-4

19

- 432 13. Derek Klarin PD, Anoop Sendamarai et al. Genome-wide Association Study of Thoracic
- 433 Aortic Aneurysm and Dissection in the Million Veteran Program. *PREPRINT (Version 1)*
- 434 available at Research Square. 2022. doi: <u>https://doi.org/10.21203/rs.3.rs-1507463/v1</u>
- 435 14. Pirruccello JP, Lin H, Khurshid S, Nekoui M, Weng LC, Vasan RS, Isselbacher EM,
- 436 Benjamin EJ, Lubitz SA, Lindsay ME, Ellinor PT. Development of a Prediction Model for
- 437 Ascending Aortic Diameter Among Asymptomatic Individuals. JAMA. 2022;328:1935-
- 438 1944. doi: 10.1001/jama.2022.19701
- 439 15. Dewey FE, Gusarova V, O'Dushlaine C, Gottesman O, Trejos J, Hunt C, Van Hout CV,
- Habegger L, Buckler D, Lai KM, et al. Inactivating Variants in ANGPTL4 and Risk of
- 441 Coronary Artery Disease. *N Engl J Med*. 2016;374:1123-1133. doi:
- 442 10.1056/NEJMoa1510926
- 16. Verma A, Damrauer SM, Naseer N, Weaver J, Kripke CM, Guare L, Sirugo G, Kember
- 444 RL, Drivas TG, Dudek SM, et al. The Penn Medicine BioBank: Towards a Genomics-
- 445 Enabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse

446 Population. *J Pers Med*. 2022;12. doi: 10.3390/jpm12121974

- 17. Hvitfeldt MKaDVaE. yardstick: Tidy Characterizations of Model Performance. 2023.
- Bland JM, Altman DG. Statistical methods for assessing agreement between two
 methods of clinical measurement. *Lancet.* 1986;1:307-310.
- 450 19. Kuhn M. tidyposterior: Bayesian Analysis to Compare Models using Resampling
 451 Statistics. 2022.
- 452 20. Kruschke JK, Liddell TM. The Bayesian New Statistics: Hypothesis testing, estimation,
- 453 meta-analysis, and power analysis from a Bayesian perspective. *Psychon Bull Rev.*
- 454 2018;25:178-206. doi: 10.3758/s13423-016-1221-4

20

- 455 21. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M. pROC: an
- 456 open-source package for R and S+ to analyze and compare ROC curves. *BMC*
- 457 *Bioinformatics*. 2011;12:77. doi: 10.1186/1471-2105-12-77
- 458 22. Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting
- 459 decision curve analysis. *Diagn Progn Res.* 2019;3:18. doi: 10.1186/s41512-019-0064-7
- 460 23. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction
- 461 models. *Med Decis Making*. 2006;26:565-574. doi: 10.1177/0272989X06295361
- 462 24. Sjoberg DD. dcurves: Decision Curve Analysis for Model Evaluation. 2022.
- 463 25. Kuhn MW, H. Tidymodels: a collection of packages for modeling and machine learning
- 464 using tidyverse principles. 2020.

21

466 Figure Legends

468	Figure 1. Between-model comparison of difference in explanation of variance (RSQ).
469	Cross-validated posterior distribution for the difference in RSQ between (A) standard AORTA
470	Score and AORTA Score + PGS; (B) reweighted AORTA Score and reweighted AORTA Score
471	+ PGS; (C) AORTA Score + PGS and reweighted AORTA Score; (D) standard AORTA Score
472	and reweighted AORTA Score + PGS. Between-model mean difference and 95% credible
473	intervals (CIs) in top right corner of each plot. PGS = polygenic score; AS = AORTA Score;
474	RSQ = <i>R</i> -squared.
475	
476	Figure 2. Logistic model receiver operator characteristic curve (ROC) and area under
477	the ROC curve to predict ascending thoracic aortic diameter \ge 4 cm. A) Receiver operator
478	characteristic curve (ROC) for each of the five models analyzed in the PMBB cohort. B) Area
479	under the ROC curves with error bars demonstrating 95% confidence intervals. PGS =
480	polygenic score; AS = AORTA Score.
481	
482	Figure 3: Individual model decision curve analysis. Decision curve analysis demonstrated
483	clinical net benefit for each model plotted against threshold probability with units representing
484	cases identified per individual screened at a specific threshold probability using a range of 0-
485	50%. Results are compared to a model that would screen all individuals ("Screen All") or
486	screen no one ("Screen None"). PGS = polygenic score; AS = AORTA Score.
487	

22

488 **Tables**

- 489 **Table 1.** Clinical characteristics of Penn Medicine Biobank individuals compared to the UKB
- 490 training cohort. UKB training dataset data taken from Pirruccello, et al.¹⁴

UK Biobank and Penn Medicine Biobank Participant Characteristics				
		UKB Training Dataset	PMBB Dataset	
		(N = 30,018)	(N = 6790)	
Sex, N (%)	Female	15635 (52.1)	2990 (44.0)	
	Male	14383 (47.9)	3800 (56.0)	
Ancestry, N (%)	European		4448 (65.5)	
	African		2116 (31.2)	
	Other		226 (3.3)	
Age in years, median (IQR)		65.1 (58.6-70.6)	61.0 (52.3-69.7)	
Medical history, N (%)	Hypertension	9009 (30.0)	5013 (73.8)	
	Hyperlipidemia	6380 (21.3)	4252 (62.6)	
	Diabetes	876 (2.9)	2204 (32.5)	
Weight in kg, median (IQR)		74.0 (64.7-84.2)	87.0 (73.6-100.5)	
Height in cm, median (IQR)		169 (162-176)	172 (164.0-180.0)	
BMI, median (IQR)		25.7 (23.4-28.5)	29.3 (25.2-33.5)	
HR in beats/ minute, median (IQR)		67.6 (61.0-75.0)	77.0 (69.8-84.2)	
Blood pressure in mmHg, median (IQR)	Systolic	138 (127-150)	127.8 (119.9-135.8)	
	Diastolic	78.5 (72.2-85.0)	73.9 (69.2-78.7)	
Ascending Aortic Diameter in cm	Mean (SD)	3.18 (0.35)	3.37 (0.50)	
	Median (IQR)	3.15 (2.93-3.40)	3.3 (2.95-3.65)	
Aortic diameter 4+ cm, N (%)		696 (2.3)	830 (12.2)	

23

492 **Table 2:** R-squared (RSQ) and Root-Mean-Square Error (RMSE) with 95% CI for each model

493 variation based on 5 repeats of 10-fold cross-validation analysis.


Model RSQ and RMSE					
Model	RSQ (95% CI)	RMSE (95% CI)			
AORTA Score	0.284 (0.276 to 0.292)	0.426 (0.423 to 0.430)			
AORTA Score + PGS	0.288 (0.281 to 0.296)	0.425 (0.421 to 0.429)			
Reweighted AORTA Score	0.304 (0.296 to 0.312)	0.420 (0.417 to 0.424)			
Reweghted AORTA Score + PGS	0.310 (0.302 to 0.318)	0.419 (0.415 to 0.422)			
Age + Sex + PGS	0.225 (0.216 to 0.234)	0.444 (0.440 to 0.448)			

494

495 CI = Credible Interval; PGS = polygenic score.

24

496 Figures




497 Figure 1. Between-model comparison of difference in explanation of variance (RSQ).

25

499 Figure 2. Logistic model receiver operator characteristic curve (ROC) and area under

500 the ROC curve to predict ascending thoracic aortic diameter \ge 4 cm.



26

503 Figure 3: Individual model decision curve analysis.

